The Biotechnology week,distilled.

Pfizer has reached an agreement to sell a scrapped antibody-drug conjugate (ADC) asset, originally acquired during its $43 billion Seagen buyout, to Medicus Pharma.

GSK has entered into a licensing agreement with Hutchmed to acquire a first-in-class oncology candidate targeting KRAS-EGFR.

Australian biotech company ENA Respiratory has secured $2.98 million in funding from the government-backed Biointelect Venturer program.

Roche has agreed to pay $190 million upfront to acquire a UCN2 analog for obesity treatment.

Roche has entered into a licensing agreement with Simcere Zaiming to acquire global rights for a preclinical trispecific antibody designed to treat B-cell-mediated diseases.

Eli Lilly has entered into a definitive agreement to acquire Merida Biosciences for a total consideration of up to $2.875 billion.

Eli Lilly and Company has announced the acquisition of Merida for $2.9 billion.

Eli Lilly & Co. has announced plans to acquire Merida Biosciences Inc. for up to $2.88 billion in cash.

Also: 04 Sep — thestreet.com

Ionis Pharmaceuticals has received regulatory approval for a treatment targeting Alexander disease, a rare genetic disorder.

The FDA has approved a new HIV combination medication developed by Gilead Sciences.

On September 4, 2026, Chinese regulatory authorities approved the world's first nine-month prophylactic antibody treatment for infant Respiratory Syncytial Virus (RSV).

The U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals' drug zilganersen, branded as Zanvastro, for the treatment of Alexander disease in children and adults.

Ionis Pharmaceuticals has received approval for Zanvastro, the first disease-modifying drug for Alexander disease.

PMV Pharmaceuticals plans to submit a regulatory filing for its drug candidate Rezatapopt in the first quarter of 2027.

The startup Atlas has launched the Atlas 1.0, a $499 wearable EEG device designed to track brain activity, electrodermal activity, and movement.

GSK and other pharmaceutical companies are seeking to enter the mRNA influenza vaccine market following the recent regulatory approval of Moderna's mRNA flu shot.

Electra Therapeutics has filed for an initial public offering (IPO) in 2026.

Global biotech startup funding in 2026 is projected to remain stable between $36 billion and $40 billion, consistent with recent years.

Genetic testing company Natera has agreed to an $8.25 million settlement to resolve a class-action lawsuit regarding the accuracy of its Panorama and Vasistera prenatal tests.

Tal Zaks, the former chief medical officer of Moderna, has seen his significant financial investment in cancer treatment research begin to yield results.

Novartis and its partner Ionis Pharmaceuticals reported that their experimental drug targeting Lp(a) failed to reduce the risk of major cardiovascular events in a Phase 3 clinical trial.

Researchers at University College London, led by Professor Jennifer Rohn, developed a 3D human micro-bladder model to study recurrent urinary tract infections (UTIs).

Researchers at Emory University conducted a study on 24 rhesus macaques infected with SIV, finding that a 10-day course of the cancer drug venetoclax, administered alongside antiretroviral therapy (ART), significantly reduced the intact viral reservoir.

Researchers from Stanford University, Xi'an Jiaotong-Liverpool University, Shanghai Jiao Tong University, and the University of Chinese Academy of Sciences discovered that plasmalogens found in sea squirts can reverse aging signs in mice.

A patient in the United States has survived for a record 271 days with a transplanted pig kidney.

Ultragenyx Pharmaceutical reported that its phase 3 clinical trial for an Angelman syndrome treatment failed to meet its primary endpoints.

Researchers at the University of Cambridge have mapped the brain of a fruit fly, identifying differences between male and female neural circuits.

Novartis and Bristol Myers Squibb have halted clinical studies for their autoimmune CAR-T cell therapies due to safety concerns.

OpenEvidence has partnered with a leading, unnamed U.S. cancer center to integrate a precision oncology knowledge base into its AI platform.

Carelon Research, led by president Mark Cziraky, has signed a partnership agreement with Manifold to enable life sciences researchers to analyze Carelon's real-world data (RWD) alongside third-party datasets.

Carelon Research and Manifold have entered into a partnership to provide Manifold's research teams with access to Carelon's real-world data (RWD) sets.

The Wall Street Journal published a market analysis on September 3, 2026, covering the healthcare sector.

The U.S. Bureau of Labor Statistics projects a 35% growth in data science occupations between 2025 and 2035, creating 95,400 new jobs.

The commercial growth of CAR-T cell therapies is currently hindered by the difficulty of scaling patient-specific manufacturing processes into a unified, reliable system.

Teva Pharmaceutical Industries reported positive results in a study for a celiac disease therapy, describing it as having 'pipeline-in-a-product' potential.

The article discusses the manufacturing challenges of CAR-T cell therapies, specifically the difficulty of scaling patient-specific production runs into a reliable system.

At the 2026 Bio-Process Systems Alliance (BPSA) International Single-Use Summit held in Boston in July, industry experts including Eric Langer of BioPlan Associates discussed the maturation of single-use technologies in biopharmaceutical manufacturing.